Phase 3 Study Comparing Daratumumab, Lenalidomide, and Dexamethasone (DRd) vs Lenalidomide and Dexamethasone (Rd) in Subjects With Relapsed or Refractory Multiple Myeloma
ID Number 14-1569Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
The purpose of this study is to look at what happens (both good and bad) when daratumumab (the experimental medication used in this study which is also known as JNJ-54767414) is given with two other drugs called lenalidomide and dexamethasone compared to just giving those two drugs, lenalidomide and dexamethasone alone. Giving lenalidomide and dexamethasone together is standard treatment for advanced multiple myeloma and is already approved to be used in many countries. The safety of daratumumab when given with lenalidomide and dexamethasone will also be studied.
Recruiting Patients: No